Advanced Biomed Inc. Common Stock (ADVB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Advanced Biomed Inc. Common Stock stock (ADVB) is currently trading at $4.04. Advanced Biomed Inc. Common Stock PE ratio is 1.18. WallStSmart rates ADVB as Sell.
- ADVB PE ratio analysis and historical PE chart
- ADVB PS ratio (Price-to-Sales) history and trend
- ADVB intrinsic value — DCF, Graham Number, EPV models
- ADVB stock price prediction 2025 2026 2027 2028 2029 2030
- ADVB fair value vs current price
- ADVB insider transactions and insider buying
- Is ADVB undervalued or overvalued?
- Advanced Biomed Inc. Common Stock financial analysis — revenue, earnings, cash flow
- ADVB Piotroski F-Score and Altman Z-Score
- ADVB analyst price target and Smart Rating
Advanced Biomed Inc.
📊 No data available
Try selecting a different time range
ADVB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Advanced Biomed Inc. Common Stock (ADVB)
ADVB trades at a significant discount to its Graham intrinsic value of $23.94, offering a 99% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Advanced Biomed Inc. Common Stock (ADVB) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/book. Concerns around market cap and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Advanced Biomed Inc. Common Stock (ADVB) Key Strengths (2)
Every $100 of shareholder equity generates $80 in profit
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Advanced Biomed Inc. Common Stock (ADVB) Areas to Watch (2)
Very low institutional interest at 0.16%
Micro-cap company with very limited liquidity and high volatility
Advanced Biomed Inc. Common Stock (ADVB) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Book. Valuation metrics including Price/Book (0.60) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 80.20%.
The Bear Case
The primary concerns are Institutional Own., Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 80.20% currently healthy but needing to be sustained. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ADVB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Compare ADVB with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Advanced Biomed Inc. Common Stock (ADVB) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Advanced Biomed Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
ROE of 8020.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -16,230, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Advanced Biomed Inc. Common Stock.
Bottom Line
Advanced Biomed Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:57 AM
About Advanced Biomed Inc. Common Stock(ADVB)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.